Format

Send to

Choose Destination
Oncoimmunology. 2015 Mar 19;4(7):e1014773. eCollection 2015 Jul.

"In situ" vaccination for systemic effects in follicular lymphoma.

Author information

1
Department of Oncology; Oslo University Hospital Radiumhospitalet ; Oslo, Norway ; K.G. Jebsen Center for Cancer Immunotherapy; Institute for Clinical Medicine; University of Oslo ; Oslo, Norway.
2
Department of Cancer Immunology; Oslo University Hospital Radiumhospitalet ; Oslo, Norway ; K.G. Jebsen Center for Cancer Immunotherapy; Institute for Clinical Medicine; University of Oslo ; Oslo, Norway.

Abstract

Therapeutic vaccines for follicular lymphoma have had limited success. A novel in situ immunotherapeutic strategy combining 3 different treatment modalities induced regression of disseminated follicular lymphoma, which correlated with systemic antitumor T-cell immunity. These results should renew interest in the development of local combined radio- and immunotherapies to achieve abscopal effects.

KEYWORDS:

abscopal; cancer vaccine; dendritic cells; follicular lymphoma; immunotherapy; radiotherapy; rituximab

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center